share_log

Shareholders in Shenzhen Kangtai Biological Products (SZSE:300601) Are in the Red If They Invested Three Years Ago

Shareholders in Shenzhen Kangtai Biological Products (SZSE:300601) Are in the Red If They Invested Three Years Ago

深圳康泰生物製品(深交所股票代碼:300601)的股東如果在三年前投資,就會陷入虧損
Simply Wall St ·  2023/10/12 11:16

While it may not be enough for some shareholders, we think it is good to see the Shenzhen Kangtai Biological Products Co., Ltd. (SZSE:300601) share price up 12% in a single quarter. But that is meagre solace in the face of the shocking decline over three years. The share price has sunk like a leaky ship, down 74% in that time. Arguably, the recent bounce is to be expected after such a bad drop. The thing to think about is whether the business has really turned around.

雖然這對一些股東來說可能還不夠,但我們認為看到深圳市康泰生物製品有限公司。(SZSE:300601)股價單季上漲12%。但面對三年來令人震驚的下滑,這只是微不足道的安慰。該公司股價像一艘漏水的船一樣下沉,在此期間下跌了74%。可以說,在經歷瞭如此嚴重的下跌之後,最近的反彈是意料之中的。需要考慮的是,企業是否真的扭虧為盈了。

So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress.

因此,讓我們來看看該公司的長期業績是否與基礎業務的進展一致。

Check out our latest analysis for Shenzhen Kangtai Biological Products

查看我們對深圳康泰生物製品的最新分析

We don't think that Shenzhen Kangtai Biological Products' modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.

我們認為,深圳康泰生物製品連續12個月的適度盈利目前還沒有得到市場的充分關注。我們認為收入可能是更好的指引。一般來說,我們會把這樣的股票和虧損的公司放在一起考慮,原因很簡單,因為利潤的總量太低了。要讓股東有信心一家公司的利潤將大幅增長,它必須增加收入。

Over three years, Shenzhen Kangtai Biological Products grew revenue at 18% per year. That's a fairly respectable growth rate. So it seems unlikely the 20% share price drop (each year) is entirely about the revenue. It could be that the losses were much larger than expected. If you buy into companies that lose money then you always risk losing money yourself. Just don't lose the lesson.

在三年的時間裡,深圳康泰生物製品的收入以每年18%的速度增長。這是一個相當可觀的增長率。因此,股價(每年)下跌20%似乎不太可能完全是因為收入。這可能是因為損失比預期要大得多。如果你買入賠錢的公司,那麼你自己總是有賠錢的風險。只要別丟了教訓就行了。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收益和收入隨時間的變化(單擊圖表查看確切的值)。

earnings-and-revenue-growth
SZSE:300601 Earnings and Revenue Growth October 12th 2023
深圳證交所:300601收益和收入增長2023年10月12日

Shenzhen Kangtai Biological Products is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. If you are thinking of buying or selling Shenzhen Kangtai Biological Products stock, you should check out this free report showing analyst consensus estimates for future profits.

深圳康泰生物製品是一隻知名的股票,有大量的分析師報道,這表明對未來的增長有一定的可見性。如果你正在考慮買賣深圳康泰生物製品的股票,你應該看看這個免費顯示分析師對未來利潤的一致估計的報告。

A Different Perspective

不同的視角

It's good to see that Shenzhen Kangtai Biological Products has rewarded shareholders with a total shareholder return of 5.7% in the last twelve months. That's including the dividend. However, the TSR over five years, coming in at 6% per year, is even more impressive. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Shenzhen Kangtai Biological Products that you should be aware of before investing here.

很高興看到深圳康泰生物製品在過去的12個月裡以5.7%的總股東回報回報了股東。這還包括股息。然而,五年來的TSR,以每年6%的速度增長,更令人印象深刻。我發現,把股價作為衡量企業業績的長期指標是非常有趣的。但為了真正獲得洞察力,我們還需要考慮其他資訊。例如,我們發現深圳康泰生物製品的3個警示標誌在這裡投資之前你應該意識到這一點。

Of course Shenzhen Kangtai Biological Products may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然了深圳康泰生物製品可能不是最值得買入的股票那就是。所以你可能想看看這個免費成長型股票的集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論